Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Anavex Life Sciences Corp.
Anavex Life Sciences Corp. News
Jul 10, 2025 - zacks.com
Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice
Jun 16, 2025 - globenewswire.com
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the Firm
Anavex Life Sciences Corp. Quantitative Score
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Anavex Life Sciences Corp. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Anavex Life Sciences Corp. Financials
Table Compare
Compare AVXL metrics with: | |||
|---|---|---|---|
Earnings & Growth | AVXL | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | AVXL | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | AVXL | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | AVXL | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Anavex Life Sciences Corp. Income
Anavex Life Sciences Corp. Balance Sheet
Anavex Life Sciences Corp. Cash Flow
Anavex Life Sciences Corp. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Anavex Life Sciences Corp. Executives
| Name | Role |
|---|---|
| Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | President, Chief Executive Officer, Secretary & Director |
| Ms. Sandra Boenisch CPA, CGA | Principal Financial Officer & Treasurer |
| Dr. Adebayo Laniyonu Ph.D. | Senior Vice President of Nonclinical Development |
| Clint Tomlinson | Vice President of Corporate |
| Dr. Edward R Hammond M.D., M.P.H., Ph.D. | Chief Medical Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | President, Chief Executive Officer, Secretary & Director | 1966 | 856.1K | |
| Ms. Sandra Boenisch CPA, CGA | Principal Financial Officer & Treasurer | Female | 1981 | 209.53K |
| Dr. Adebayo Laniyonu Ph.D. | Senior Vice President of Nonclinical Development | -- | ||
| Clint Tomlinson | Vice President of Corporate | -- | ||
| Dr. Edward R Hammond M.D., M.P.H., Ph.D. | Chief Medical Officer | -- |
Anavex Life Sciences Corp. Insider Trades
| Date | 5 Jun |
| Name | Thomas Steffen |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 50000 |
| Date | 5 Jun |
| Name | Thomas Steffen |
| Role | Director |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 11349 |
| Date | 5 Jun |
| Name | Thomas Steffen |
| Role | Director |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 50000 |
| Date | 28 Apr |
| Name | Boenisch Sandra |
| Role | PFO & Treasurer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 12500 |
| Date | 28 Apr |
| Name | MISSLING CHRISTOPHER U |
| Role | President and CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 125000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 5 Jun | Thomas Steffen | Director | Acquired | M-Exempt | 50000 |
| 5 Jun | Thomas Steffen | Director | Disposed | F-InKind | 11349 |
| 5 Jun | Thomas Steffen | Director | Disposed | M-Exempt | 50000 |
| 28 Apr | Boenisch Sandra | PFO & Treasurer | Acquired | A-Award | 12500 |
| 28 Apr | MISSLING CHRISTOPHER U | President and CEO | Acquired | A-Award | 125000 |